Biochemistry, Genetics and Molecular Biology
Myeloid
94%
ETV6
81%
Proteogenomics
54%
Receptor Tyrosine Kinase
40%
Proteomics
39%
Kinase
36%
Phosphotransferase
36%
Drug Response
36%
Eicosanoid Receptor
34%
Insulin-Like Growth Factor 1 Receptor
33%
Drug Sensitivity
27%
Mesenchymal-Epithelial Transition
24%
Mediator
23%
Phosphoproteomics
23%
Carcinogenesis
22%
Fusion Protein
21%
Gene Fusion
21%
Oncogene
20%
Insulin Receptor
19%
Fibroblast
19%
Guanine Nucleotide Exchange Factor
19%
Cancer Cell
18%
Mouse
18%
Ruxolitinib
18%
Cytokine
16%
Cell Proliferation
16%
Diacylglycerol
16%
Genetics
16%
C1 Domain
15%
Gene Expression
14%
Cell Transformation
14%
Transcriptomics
14%
Point Mutation
14%
Tyrosine Kinase
14%
Y Box Binding Protein 1
13%
Tyrosine Kinase Inhibitor
12%
Transcription Factors
12%
Fusion Gene
12%
Colony Formation
12%
Epidermal Growth Factor Receptor
12%
Functional Genomics
12%
Metabolomics
10%
Phosphoinositide 3-Kinase
10%
Translational Regulation
10%
Ponatinib
10%
Protein Kinase C
10%
Tyrosine Phosphorylation
9%
Cell Membrane
9%
Trematode
9%
FANCL
9%
Medicine and Dentistry
Acute Myeloid Leukemia
100%
Ex Vivo
49%
Leukemia
40%
Malignant Neoplasm
38%
Phosphotransferase
33%
Drug Sensitivity
30%
Neoplasm
28%
Drug Response
27%
Mediator
27%
Gene Expression
25%
Targeted Therapy
21%
Disease
21%
Fusion Protein
21%
Venetoclax
21%
Hematologic Malignancy
20%
Protein Tyrosine Kinase
20%
Chronic Neutrophilic Leukemia
18%
Metastatic Carcinoma
18%
Fibrosarcoma
15%
Functional Genomics
14%
Receptor
12%
Chronic Myelogenous Leukemia
12%
Mitogen-Activated Protein Kinase
12%
Leukemia Cell
12%
Combination Drug
12%
Pediatrics Patient
12%
Proteomics
12%
Oncology
12%
Cytokine
12%
In Vitro
11%
Ruxolitinib
10%
RNA Sequence
10%
Fusion Gene
9%
Mesoblastic Nephroma
9%
Breast Carcinoma
9%
Drug Activity
9%
Interleukin 2 Receptor Gamma
9%
Wound Healing
9%
Growth Factor Receptor
9%
Phosphatidylinositol
9%
Entrectinib
9%
Carcinoma Cell
9%
RNA Interference
9%
Atypical Chronic Myeloid Leukemia
9%
Protein Phosphorylation
9%
Epithelioma
9%
Hypoxia Inducible Factor 1
9%
Protein Synthesis
9%
T Cell
9%
Point Mutation
9%
Keyphrases
Acute Myeloid Leukemia
63%
ETV6-NTRK3 Fusion
27%
Proteogenomics
27%
ETV6-NTRK3
22%
Leukemia
22%
Chronic Myeloid Leukemia
21%
Translational Activation
18%
YB-1
18%
Bcl-2 Inhibitor
18%
NT157
18%
Insulin-like Growth Factor 1 Receptor (IGF1R)
18%
Targeted Therapy
15%
Leukemia Patients
15%
Drug Response
15%
Venetoclax
15%
Gene Expression
15%
BCR-ABL1
15%
Oncogene
15%
FLT3 mutation
13%
Epithelial-mesenchymal Transition
13%
Precision Medicine
13%
Proteomics
13%
Drug Sensitivity
12%
Pediatric Patients
12%
Secretory Breast Carcinoma
12%
High Risk
12%
Fusion Protein
10%
Bone Marrow Microenvironment
10%
Translational Regulation
10%
Tumor
10%
Kinase Activation
10%
Complementary DNA (cDNA)
10%
Protein Kinase
10%
Therapeutic Potential
10%
FMS-like Tyrosine Kinase 3 (FLT3)
10%
Molecular Characterization
10%
Point mutation
9%
Guanine nucleotide Exchange Factor
9%
Phosphoinositide 3-kinase (PI3K)
9%
Growth Hormone Receptor
9%
Blood Fluke
9%
Steady State
9%
Endometrial Carcinoma
9%
Gilteritinib
9%
Clear Cell Renal Cell Carcinoma (ccRCC)
9%
Genomic Markers
9%
ABL1 Kinase
9%
Phorbol Ester
9%
Philadelphia Chromosome
9%
FANCL
9%
